Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016

  • ID: 3961129
  • Report
  • 122 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amorsa Therapeutics Inc.
  • Biogen Inc
  • Johnson & Johnson
  • Mapi Pharma Ltd.
  • Omeros Corporation
  • Pfizer Inc.
  • MORE
Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016

The latest Pharmaceutical and Healthcare disease pipeline guide Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016, provides an overview of the Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline landscape.

Bipolar disorder was formerly called manic depression. It is a form of major affective disorder, or mood disorder, defined by manic or hypomanic episodes. Symptoms include decreased appetite and/or weight loss, or overeating and weight gain, fatigue, decreased energy, being slowed down, insomnia, early-morning awakening, or oversleeping, restlessness and irritability. The predisposing factors include age, stress and family history. Treatment includes anticonvulsants, antipsychotics and antidepressants.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 10, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.Bipolar Disorder (Manic Depression).

Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amorsa Therapeutics Inc.
  • Biogen Inc
  • Johnson & Johnson
  • Mapi Pharma Ltd.
  • Omeros Corporation
  • Pfizer Inc.
  • MORE
Introduction

Bipolar Disorder (Manic Depression) Overview

Therapeutics Development

Pipeline Products for Bipolar Disorder (Manic Depression) - Overview

Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis

Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies

Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes

Bipolar Disorder (Manic Depression) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Bipolar Disorder (Manic Depression) - Products under Development by Companies

Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes

Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development

Aequus Pharmaceuticals Inc.

Amorsa Therapeutics Inc.

AstraZeneca Plc

Biogen Inc

Delpor, Inc.

Intas Pharmaceuticals Ltd.

Intra-Cellular Therapies, Inc.

Johnson & Johnson

KemPharm, Inc.

Mapi Pharma Ltd.

Navya Biologicals Pvt Ltd

Neurocrine Biosciences Inc

Omeros Corporation

Otsuka Holdings Co., Ltd.

Pfizer Inc.

Reviva Pharmaceuticals Inc.

SK Biopharmaceuticals Co., Ltd.

Sumitomo Dainippon Pharma Co Ltd

Zogenix, Inc.

Zysis Limited

Bipolar Disorder (Manic Depression) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(cycloserine + lurasidone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aripiprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aripiprazole CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aripiprazole ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-1407 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-2803 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cenobamate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNV-1061436 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ebselen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Endoxifen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITI-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-18038683 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lurasidone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paliperidone palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGW-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

quetiapine fumarate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

risperidone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

risperidone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

risperidone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-PSY - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Bipolar Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Cancer and Neurodegenerative Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit VMAT-2 for Bipolar Disorder, Movement Disorders and Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target GPR50 for Bipolar Disorder and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target NMDA Receptor for Bipolar Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ziprasidone mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bipolar Disorder (Manic Depression) - Dormant Projects

Bipolar Disorder (Manic Depression) - Discontinued Products

Bipolar Disorder (Manic Depression) - Product Development Milestones

Featured News & Press Releases

Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia

Oct 18, 2016: NeuroRx Solidifies Intellectual Property Position Receives Notice of Allowance by US Patent Office

Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress

Aug 09, 2016: Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan

Jun 01, 2016: NeuroRx Awarded First Prize in Annual Israel BIOMED Startup Competition

May 23, 2016: Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression

May 12, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 169th Annual Meeting of the American Psychiatric Association

Feb 25, 2016: Intra-Cellular Therapies Provides Product Update

Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch

Dec 23, 2015: Intra-Cellular Therapies Reports Initiation of Patient Enrollment for ITI-007 Phase 3 Clinical Trials in Bipolar Depression

Dec 16, 2015: NeuroRx Provides Clinical Development Update for Cyclurad, a Novel Treatment for Acute Suicidal Crisis in Bipolar Disorder

Nov 16, 2015: Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch

Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole

Jul 22, 2015: Intra-Cellular Therapies Announces Phase 3 Clinical Development Program for the Treatment of Depressive Episodes Associated With Bipolar Disorder

May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016

Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Aequus Pharmaceuticals Inc., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Amorsa Therapeutics Inc., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca Plc, H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Biogen Inc, H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Johnson & Johnson, H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Mapi Pharma Ltd., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Navya Biologicals Pvt Ltd, H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Neurocrine Biosciences Inc, H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H2 2016

Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Bipolar Disorder (Manic Depression) - Dormant Projects, H2 2016

Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..1), H2 2016

Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..2), H2 2016

Bipolar Disorder (Manic Depression) - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016

Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aequus Pharmaceuticals Inc.
  • Amorsa Therapeutics Inc.
  • AstraZeneca Plc
  • Biogen Inc
  • Delpor, Inc.
  • Intas Pharmaceuticals Ltd.
  • Intra-Cellular Therapies, Inc.
  • Johnson & Johnson
  • KemPharm, Inc.
  • Mapi Pharma Ltd.
  • Navya Biologicals Pvt Ltd
  • Neurocrine Biosciences Inc
  • Omeros Corporation
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • Sumitomo Dainippon Pharma Co Ltd
  • Zogenix, Inc.
  • Zysis Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll